Latest Insider Transactions at C4 Therapeutics, Inc. (CCCC)
This section provides a real-time view of insider transactions for C4 Therapeutics, Inc. (CCCC). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of C4 Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of C4 Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Apr 14
2021
|
Kenneth Carl Anderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
711
+0.42%
|
$2,133
$3.55 P/Share
|
Apr 13
2021
|
Kenneth Carl Anderson Director |
BUY
Bona fide gift
|
Indirect |
2,278
+4.59%
|
-
|
Apr 13
2021
|
Kenneth Carl Anderson Director |
BUY
Bona fide gift
|
Direct |
2,278
+2.63%
|
-
|
Apr 05
2021
|
Marc A Cohen Director |
BUY
Grant, award, or other acquisition
|
Direct |
553
+8.29%
|
$20,461
$37.51 P/Share
|
Apr 05
2021
|
Alain J Cohen Director |
BUY
Grant, award, or other acquisition
|
Direct |
266
+50.0%
|
$9,842
$37.51 P/Share
|
Apr 05
2021
|
Malcolm Salter Director |
BUY
Grant, award, or other acquisition
|
Direct |
359
+2.15%
|
$13,283
$37.51 P/Share
|
Apr 05
2021
|
Adam Crystal Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
15,000
-63.74%
|
$555,000
$37.58 P/Share
|
Apr 05
2021
|
Adam Crystal Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$90,000
$6.5 P/Share
|
Apr 05
2021
|
Kenneth Carl Anderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
233
+0.28%
|
$8,621
$37.51 P/Share
|
Feb 18
2021
|
Marc A Cohen Director |
BUY
Exercise of conversion of derivative security
|
Direct |
536
+8.78%
|
$1,072
$2.11 P/Share
|
Feb 03
2021
|
Stewart Fisher Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,300
+3.73%
|
$16,600
$2.91 P/Share
|
Jan 22
2021
|
Kenneth Carl Anderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,548
+0.63%
|
$4,644
$3.07 P/Share
|
Dec 11
2020
|
Stewart Fisher Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,444
+6.93%
|
$28,888
$2.91 P/Share
|
Oct 06
2020
|
Elena Prokupets Director |
BUY
Conversion of derivative security
|
Indirect |
711,447
+50.0%
|
-
|
Oct 06
2020
|
Alain J Cohen Director |
BUY
Conversion of derivative security
|
Indirect |
4,203,757
+48.77%
|
-
|
Oct 06
2020
|
Malcolm Salter Director |
BUY
Open market or private purchase
|
Direct |
1,315
+7.6%
|
$24,985
$19.0 P/Share
|
Oct 06
2020
|
Malcolm Salter Director |
BUY
Conversion of derivative security
|
Direct |
14,679
+33.06%
|
-
|
Oct 06
2020
|
Bruce Downey Director |
BUY
Conversion of derivative security
|
Direct |
489,542
+42.01%
|
-
|
Oct 06
2020
|
Kenneth Carl Anderson Director |
BUY
Conversion of derivative security
|
Indirect |
134,406
+41.46%
|
-
|
Oct 06
2020
|
Kenneth Carl Anderson Director |
BUY
Conversion of derivative security
|
Direct |
18,040
+18.33%
|
-
|
Oct 06
2020
|
Marc A Cohen Director |
BUY
Open market or private purchase
|
Direct |
5,030
+50.0%
|
$95,570
$19.0 P/Share
|
Oct 06
2020
|
Marc A Cohen Director |
BUY
Conversion of derivative security
|
Indirect |
4,203,757
+44.5%
|
-
|
Oct 06
2020
|
William Mckee Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
5,263
+50.0%
|
$99,997
$19.0 P/Share
|